Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRI-guided laser ablation of neuroendocrine tumor hepatic metastases.
Perälä J, Klemola R, Kallio R, Li C, Vihriälä I, Salmela PI, Tervonen O, Sequeiros RB. Perälä J, et al. Among authors: vihriala i. Acta Radiol Short Rep. 2014 Jan 23;3(1):2047981613499753. doi: 10.1177/2047981613499753. eCollection 2014 Jan. Acta Radiol Short Rep. 2014. PMID: 24778794 Free PMC article.
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: vihriala i. Scand J Gastroenterol. 2018 Feb;53(2):158-167. doi: 10.1080/00365521.2017.1416160. Epub 2017 Dec 19. Scand J Gastroenterol. 2018. PMID: 29258369
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: vihriala i. Biologicals. 2019 Mar;58:50-56. doi: 10.1016/j.biologicals.2019.01.007. Epub 2019 Feb 10. Biologicals. 2019. PMID: 30755369 Clinical Trial.
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A, Hallinen T, Af Björkesten CG, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen UM, Utriainen K, Vihriälä I, Soini E, Wennerström C, Nissinen R, Borsi A, Koivunen M, Tillonen J, Sipponen T. Eberl A, et al. Among authors: vihriala i. Scand J Gastroenterol. 2019 Jun;54(6):718-725. doi: 10.1080/00365521.2019.1624817. Epub 2019 Jun 11. Scand J Gastroenterol. 2019. PMID: 31184512 Free article.
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
Af Björkesten CG, Ilus T, Hallinen T, Soini E, Eberl A, Hakala K, Heikura M, Jussila A, Koskela R, Koskinen I, Moilanen V, Nielsen C, Nieminen U, Nuutinen H, Heikkinen M, Suhonen UM, Tillonen J, Utriainen K, Vihriälä I, Wennerström C, Borsi A, Nissinen R, Koivunen MR, Sipponen T. Af Björkesten CG, et al. Among authors: vihriala i. Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1507-1513. doi: 10.1097/MEG.0000000000001831. Eur J Gastroenterol Hepatol. 2020. PMID: 32868649 Free PMC article.